Literature DB >> 33528649

A novel EyePhone© App for improving adherence to glaucoma therapy.

Ari Leshno1,2, Dan Gaton3,4,5, Reut Singer6,3, Elior Eliasi3, Ofri Vorobichik-Berar6, Shiran Madgar6, Ori Stern6,3, Wasim Jaber6,3, Noa Kapelushnik6,3, Alon Skaat6,3.   

Abstract

PURPOSE: Despite advances in glaucoma treatment options, patient adherence and compliance remain very low. The EyePhone© App is a free non-commercial reminder application designed specifically for the needs of glaucoma patients. In this study, we evaluated its usefulness in improving adherence to medical treatment among glaucoma patients.
METHODS: This is a prospective multicenter interventional study. Glaucoma patients were recruited from a tertiary center and a large community glaucoma service center. After a short explanation, the EyePhone© App was installed on their smartphone device, and the notifications for the current medical treatment were entered. After enrollment and at 1-month follow-up, subjects completed the Morisky Medication Adherence Scale (MMAS-8) and the Quality of Life and Glaucoma 17-item (GlauQOL-17) questionnaires for evaluation of adherence and QOL, respectively.
RESULTS: In the study, 133 patients (71 men and 62 women) aged 62±15.5 years and using 2.0±0.9 IOP-lowering drugs participated. The proportion of highly adherent subjects improved from 29.3% (39/133) at baseline to 42.1% (56/133) at follow-up (P < 0.001), and the proportion of poorly adherent subjects decreased from 29.3 (39/133) to 20.3% (27/133) at follow-up (P = 0.012). QOL also improved, as evidenced by a significant increase in the GlauQOL-17 score (P < 0.05). In a subgroup of patients for whom IOP measurements were available, IOP reduced by 0.92 mmHg (P = 0.069).
CONCLUSIONS: Significant improvements in glaucoma adherence and QOL were achieved among poorly adherent glaucoma patients after 1 month of using the EyePhone© App.

Entities:  

Keywords:  Adherence; Application; Glaucoma; Quality of life; Smartphone

Year:  2021        PMID: 33528649     DOI: 10.1007/s00417-021-05091-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

Review 1.  Number of people with glaucoma worldwide.

Authors:  H A Quigley
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

2.  Cost-Utility Analysis of Glaucoma Medication Adherence.

Authors:  Paula Anne Newman-Casey; Mariam Salman; Paul P Lee; Justin D Gatwood
Journal:  Ophthalmology       Date:  2019-10-10       Impact factor: 12.079

Review 3.  Emerging risk factors for glaucoma onset and progression.

Authors:  Dana Blumberg; Alon Skaat; Jeffrey M Liebmann
Journal:  Prog Brain Res       Date:  2015-07-02       Impact factor: 2.453

Review 4.  Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.

Authors:  Christine M G Olthoff; Jan S A G Schouten; Bart W van de Borne; Carroll A B Webers
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

5.  Do adherence rates and glaucomatous visual field progression correlate?

Authors:  Gemma C M Rossi; Gian Maria Pasinetti; Luigia Scudeller; Rosella Radaelli; Paolo Emilio Bianchi
Journal:  Eur J Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 2.597

6.  Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head.

Authors:  W C Stewart; R P Chorak; H H Hunt; G Sethuraman
Journal:  Am J Ophthalmol       Date:  1993-08-15       Impact factor: 5.258

Review 7.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

Authors:  Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

8.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01

9.  Are you compliant with addressing glaucoma adherence?

Authors:  Steven L Mansberger
Journal:  Am J Ophthalmol       Date:  2010-01       Impact factor: 5.258

10.  Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.

Authors:  Gregory Reardon; Sameer Kotak; Gail F Schwartz
Journal:  Patient Prefer Adherence       Date:  2011-09-23       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.